Chen W.,Center for Breast Diseases Diagnosis and Treatment |
He J.,Center for Breast Diseases Diagnosis and Treatment |
Wu H.,Center for Breast Diseases Diagnosis and Treatment |
Wang M.,Center for Breast Diseases Diagnosis and Treatment |
And 2 more authors.
Chinese Journal of Clinical Oncology | Year: 2014
Objective: To observe the efficacy of neo-adjuvant chemotherapy with TCH and TAC regimens on the treatment of breast cancer caused by HER-2 over-expression. Methods: A total of 64 HER-2 over-expression breast cancer patients were randomly divided into two groups. In the group treated with the TCH regimen, 39 patients underwent the Trastuzumab treatment combined with Docetaxel and Carboplatin. In the group treated with the TAC regimen, 25 patients underwent therapy using Docetaxel, Epirubicin, and Cyclophosphamide. Neo-adjuvant chemotherapy was continued for six cycles until a comparison of the therapeutic effects was made. Results: The overall responses (OR) of patients in the two groups-TCG and TAC-were 94.9% (37/39) and 72% (18/25), respectively, P<0.05. The pathologic complete responses (pCR) were 69.2% (27/39) and 32.0% (8/25), respectively, P<0.05. No significant differences were observed between the two groups in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression, and liver function impairment. Conclusion: During the treatment of HER-2 over-expressing breast cancer patients with neoadjuvant chemotherapy, Trastuzumab combined with Docetaxel and Carboplatin showed a favorable efficacy and a high pCR rate. Source